Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma

J Natl Cancer Inst. 2014 Dec 3;107(1):378. doi: 10.1093/jnci/dju378. Print 2015 Jan.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Ameloblastoma / diagnostic imaging
  • Ameloblastoma / drug therapy*
  • Ameloblastoma / genetics
  • Ameloblastoma / pathology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Black or African American / statistics & numerical data
  • Compassionate Use Trials*
  • Glutamic Acid
  • Humans
  • Imidazoles / administration & dosage
  • Imidazoles / adverse effects
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / secondary
  • Male
  • Mandibular Neoplasms / diagnostic imaging
  • Mandibular Neoplasms / drug therapy*
  • Mandibular Neoplasms / genetics
  • Mandibular Neoplasms / pathology
  • Molecular Targeted Therapy / methods*
  • Mutation*
  • Neoplasm Recurrence, Local / diagnostic imaging
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Staging
  • Oximes / administration & dosage
  • Oximes / adverse effects
  • Proto-Oncogene Proteins B-raf / genetics*
  • Pyridones / administration & dosage
  • Pyridones / adverse effects
  • Pyrimidinones / administration & dosage
  • Pyrimidinones / adverse effects
  • Radiography
  • Treatment Outcome
  • Valine

Substances

  • Imidazoles
  • Oximes
  • Pyridones
  • Pyrimidinones
  • trametinib
  • Glutamic Acid
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • Valine
  • dabrafenib